Cochrane · systematic review · CD010496
Probiotics for vulvovaginal candidiasis in non‐pregnant women
Xie, HY, Feng, D, Wei, DM, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Sexually Transmitted InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 50%Low 3 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Probiotics used as adjuvants to conventional antifungal drugs compared with conventional antifungal drugs for the treatment of vulvovaginal candidiasis in non‐pregnant women
Population: non‐pregnant women with vulvovaginal candidiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical cure rate (short‐term) Probiotics used as adjuvants to conventional antifungal drugs vs conventional antifungal drugs | RR 1.14 [1.05, 1.24] | 5 studies · 695 participants | Low Downgraded: risk of bias |
Clinical cure rate (long‐term) Probiotics used as adjuvants to conventional antifungal drugs vs conventional antifungal drugs | RR 1.07 [0.86, 1.33] | 1 study · 172 participants | Very low Downgraded: risk of bias |
Mycological cure rate (short‐term) Probiotics used as adjuvants to conventional antifungal drugs vs conventional antifungal drugs | RR 1.06 [1.02, 1.1] | 7 studies · 969 participants | Low Downgraded: risk of bias |
Mycological cure rate (long‐term) Probiotics used as adjuvants to conventional antifungal drugs vs conventional antifungal drugs | RR 1.26 [0.93, 1.71] | 3 studies · 627 participants | Very low Downgraded: risk of bias |
Relapse rate Probiotics used as adjuvants to conventional antifungal drugs vs conventional antifungal drugs | RR 0.34 [0.17, 0.68] | 3 studies · 388 participants | Very low Downgraded: risk of bias |
Rate of serious adverse events Probiotics used as adjuvants to conventional antifungal drugs vs conventional antifungal drugs | RR 0.8 [0.22, 2.94] | 2 studies · 440 participants | Low Downgraded: risk of bias |